International
The Morning Science

What science found today

‹
 

News

FDA approves new drug for advanced head and neck squamous cell carcinoma

Medical Xpress ·

FDA approves new drug for advanced head and neck squamous cell carcinoma

The Brief

  • The US Food and Drug Administration (FDA) has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) from Janssen Biotech.
  • The approval covers adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed during or after prior treatment.
  • The source article is dated 2026-11-18 and reports the approval; the exact approval date is not stated in the available text.

Why it matters

It adds an FDA-approved treatment option for a group of advanced head and neck squamous cell carcinoma patients whose disease has progressed, a setting where options are limited.

Who’s affected

  • oncologists and clinicians treating head and neck squamous cell carcinoma
  • patients with recurrent or metastatic head and neck squamous cell carcinoma

The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt…

Timeline

  1. FDA approval of Rybrevant Faspro for HNSCC reported by Medical Xpress

  2. Medical Xpress - latest medical and health news stories

    FDA approves new drug for advanced head and neck squamous cell carcinoma

How do you feel about this?

0 Comments

    FDA approves new drug for advanced head and neck squamous cell carcinoma – The Morning Science